

Bibliography for AMCP NSCLC

- Arnall JR, Petro R, Patel JN, Kennedy L. A clinical pharmacy pilot within a precision medicine program for cancer patients and review of related pharmacist clinical practice. *J Oncol Pharm Pract.* 2019;25(1):179–186.
- Bauml J, Levy B. Clonal hematopoiesis: a new layer in the liquid biopsy story in lung cancer. *Clin Cancer Res.* 2018;24(18):4352–4354.
- Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small-cell lung cancer in the global phase III ALEX Study [published correction appears in: *J Thorac Oncol.* 2019;14(11):2023]. *J Thorac Oncol.* 2019;14(7):1233–1243
- Doebele R, Paz-Ares L, Farago AF, et al. Entrectinib in *NTRK*-fusion positive (*NTRK*-FP) non-small-cell lung cancer (NSCLC): integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001). Abstract CT131. Presented at: the American Association for Cancer Research Annual Meeting; March 29–April 3, 2019; Atlanta, Georgia.
- Drilon A, Barlesi F, De Braud F, et al. Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer (NSCLC): integrated analysis of ALKA-371-001, STARTRK-1, and STARTRK-2. Abstract CT192. Presented at: American Association for Cancer Research Annual Meeting; March 29–April 3, 2019; Atlanta, Georgia.
- Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. *Nat Med.* 2020;26(1):47–51.
- Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med.* 2018;378(8):731–739.
- Drilon A, Oxnard G, Wirth L, et al. Registrational results of LIBRETTO-001: a phase 1/2 trial of loxo-292 in patients with *RET* fusion-positive lung cancers. Abstract PL02-88. Presented at: 2019 World Conference on Lung Cancer; September 7–10, 2019; Barcelona, Spain.
- Drilon A, Zhai D, Deng W, et al. Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations. Abstract 442. Presented at: American Association for Cancer Research Annual Meeting; March 29–April 3, 2019; Atlanta, Georgia.
- Farago AF, Taylor MS, Doebele RC, et al. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an *NTRK* Gene Fusion. *JCO Precis Oncol.* 2018;2018:PO.18.00037.
- Gadgeel S, Peters S, Mok T, et al. Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study. Abstract 12980_PR. Presented at: European Society for Medical Oncology 2017 Congress; September 11, 2017; Madrid, Spain.
- Gainor JF, Lee DH, Curigliano G, et al. Clinical activity and tolerability of BLU-667, a highly potent and selective *RET* inhibitor, in patients (pts) with advanced *RET*-fusion+ non-small-cell lung cancer (NSCLC). Abstract 9008. Presented at: ASCO Annual Meeting 2019; June 3, 2019; Chicago, Illinois. *J Clin Oncol.* 2019;37(15_suppl):9008.
- Gainor JF, Curigliano G, Kim D, et al. Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced *RET* fusion+ non-small cell lung cancer (NSCLC). Abstract 9515. Presented at the 2020 ASCO Virtual Scientific Program. May 29 – June 2, 2020.
- Goto K, Oxnard GR, Tan DSW, et al. Selpercatinib (LOXO-292) in patients with *RET*-fusion+ non-small cell lung cancer. Abstract 3584. Presented at: ASCO Annual Meeting 2020 Virtual Scientific Program. May 29 – June 2, 2020.
- Hiley CT, Le Quesne J, Santis G, et al. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. *Lancet.* 2016;388(10048):1002-1011.
- Husain H, Velculescu VE. Cancer DNA in the Circulation: The Liquid Biopsy. *JAMA.* 2017;318(13):1272-1274.

- Cancer Genetics Overview (PDQ®) – Health Professional Version. National Cancer Institute website. July 24, 2020. https://www.cancer.gov/about-cancer/causes-prevention/genetics/overview-pdq#link/_2594. Accessed October 2020.
- Johnsen JM, Nickerson DA, Reiner AP. Massively parallel sequencing: the new frontier of hematologic genomics. *Blood*. 2013;122(19):3268–3275.
- Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline update. *J Clin Oncol*. 2018;36(9):911–919.
- Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer [published correction appears in: *N Engl J Med*. 2011;364(6):588]. *N Engl J Med*. 2010;363(18):1693–1703.
- Lan S, Shun L. Crizotinib versus pemetrexed-based chemotherapy in patients with advanced ROS1-rearranged non–small-cell lung cancer. *J Clin Oncol*. 2019;37(15_suppl):9101–9101.
- Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non–small-cell lung cancer. *Clin Cancer Res*. 2019;25(15):4691–4700.
- Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in *EGFR*-mutated non-small cell lung cancer. *Br J Cancer*. 2019;121(9):725–737.
- Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *J Thorac Oncol*. 2018;13:323–358.
- Lisberg A, Cummings A, Goldman JW, et al. A phase II study of pembrolizumab in *EGFR*-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. *J Thorac Oncol*. 2018;13(8):1138–1145.
- Lui C, Cady N, Batt C. Nucleic acid-based detection of bacterial pathogens using integrated microfluidic platform systems. *Sensors* (Basel, Switzerland). 2009;9(5):3713–3744.
- McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer [published correction appears in: *JAMA Oncol*. 2016;2(1):146]. *JAMA Oncol*. 2016;2(1):46–54.
- Mok TS, Wu Y-L, Ahn M-J, et al; AURA3 Investigators. Osimertinib or platinum-pemetrexed in *EGFR* T790M–positive lung cancer. *N Engl J Med*. 2017;376(7):629–640.
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*. 2009;361(10):947–957.
- Nakagawa K, Garon EB, Seto T, et al; RELAY Study Investigators. Ramucirumab plus erlotinib in patients with untreated, *EGFR*-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2019;20(12):1655–1669.
- National Comprehensive Cancer Network. NCCN guidelines: non–small-cell lung cancer. Version 8.2020. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed October 2020.
- Pao W, Hutchinson KE. Chipping away at the lung cancer genome. *Nat Med*. 2012;18(3):349–351.
- Pennell NA, Arcila ME, Gandara DR, West H. Biomarker testing for patients with advanced non–small cell lung cancer: real-world issues and tough choices. *ASCO Educational Book*. 2019;39:531–542.
- Peters S, Camidge DR, Shaw AT, et al; ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. *N Engl J Med*. 2017;377(9):829–838.
- Planchard D, Popat S, Kerr K, et al; ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018;29(Suppl_4):iv192–iv237.

- Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. *Lancet Oncol.* 2017;18(10):1307–1316.
- Ramalingam SS, Gray JE, Ohe Y, et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis. *Ann Oncol.* 2019;30(Suppl_5):v851–v934.
- Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. *N Engl J Med.* 2020;382(1):41–50.
- Ramalingam SS, Yang JCH, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. *J Clin Oncol.* 2018;36(9):841–849.
- Rolfo C, Mack PC, Scagliotti GV, et al. Liquid biopsy for advanced non-small-cell lung cancer (NSCLC): a statement paper from the IASLC. *J Thorac Oncol.* 2018;13(9):1248–1268.
- Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 2012;13(3):239–246.
- Saadeh C, Bright D, Rustem D. Precision medicine in oncology pharmacy practice. *Acta Med Acad.* 2019;48(1):90–104.
- Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. *Ann Oncol.* 2019;30(5):839–844.
- Schoenfeld AJ, Chan JM, Kubota D, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. *Clin Cancer Res.* 2020;26(11):2654–2663.
- Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med.* 2011;3(75):75ra26.
- Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. *J Clin Oncol.* 2013;31(27):3327–3334.
- Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. *Lancet Oncol.* 2017;18(12):1590–1599.
- Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. *Ann Oncol.* 2019;30(7):1121–1126.
- Shaw AT, Solomon BJ, Besse B, et al. ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. *J Clin Oncol.* 2019;37(16):1370–1379.
- Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. *Lancet Oncol.* 2019;20(12):1691–1701.
- Singal G, Miller PG, Agarwala V, et al. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. *JAMA.* 2019;321(14):1391–1399.
- Socinski MA, Jotte RM, Cappuzzo F, et al; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med.* 2018;378(24):2288–2301.
- Solomon BJ, Mok T, Kim DW, et al; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer [published correction appears in: *N Engl J Med.* 2015;373(16):1582]. *N Engl J Med.* 2014;371(23):2167–2177.
- Soria JC, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med.* 2018;378(2):113–125.

Subbiah V, Hu MI, Gainor JF, et al. Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Abstract 109. Presented at the 2020 ASCO Virtual Scientific Program. May 29 – June 2, 2020.

Trivedi H, Acharya D, Chamarthy U, et al. Implementation and outcomes of a molecular tumor board at Herbert-Herman Cancer Center, Sparrow Hospital. *Acta Med Acad.* 2019;48(1):105–115.

Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint Phase 1 Project. *J Thorac Oncol.* 2018;13(9):1302–1311.

Walko C, Kiel PJ, Kolesar J. Precision medicine in oncology: New practice models and roles for oncology pharmacists. *Am J Health Syst Pharm.* 2016;73(23):1935–1942.

Wolf J, Overbeck TR, Han J, et al. Capmatinib in patients with high-level MET-amplified non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Abstract 9509. Presented at the 2020 ASCO Virtual Scientific Program. May 29 – June 2, 2020.

Wolf J, Seto T, Han J, et al. Capmatinib (INC280) in METex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. Abstract 9004. Presented at the American Society of Clinical Oncology Annual Meeting; May 31 – June 4, 2019; Chicago, Illinois.